AN2 Therapeutics (ANTX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.38, -6.11% vs the prior close of $3.60.
- Volume 281.73K shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ANTX slides 6.1% to $3.38, a 6-month low. Closed at $3.38, -6.11% vs the prior close of $3.60. Day range $3.30–$3.62, opened at $3.60.
ANTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ANTX slides 6.1% to $3.38, a 6-month low
- Closed at $3.38, -6.11% vs the prior close of $3.60. Day range $3.30–$3.62, opened at $3.60.
- Volume was 281.73K shares, 1.1x its 50-day average of 263.73K.
- Price is -36.3% vs its 50-day average ($5.31) and -14.1% vs its 200-day average ($3.93).
- 52-week range $1.00–$7.19; today's close sits at 38% of that range, 53.0% below the 52-week high.
Oct 15, 2026 — ANTX rises 1.7% to $3.60
- Closed at $3.60, +1.69% vs the prior close of $3.54. Day range $3.50–$3.69, opened at $3.50.
- Volume was 295.90K shares, 1.1x its 50-day average of 260.73K.
- Price is -32.8% vs its 50-day average ($5.36) and -8.2% vs its 200-day average ($3.92).
- 52-week range $1.00–$7.19; today's close sits at 42% of that range, 49.9% below the 52-week high.
Oct 14, 2026 — ANTX dips 1.7% to $3.54, a 3-month low, 8 down days in a row
- Closed at $3.54, -1.67% vs the prior close of $3.60. Day range $3.33–$3.73, opened at $3.55.
- Volume was 431.00K shares, 1.7x its 50-day average of 259.48K.
- Price is -34.5% vs its 50-day average ($5.40) and -9.5% vs its 200-day average ($3.91).
- 52-week range $1.00–$7.19; today's close sits at 41% of that range, 50.8% below the 52-week high.
- That makes 8 straight losses.
Oct 13, 2026 — ANTX slides 16.3% to $3.60, a 3-month low on 2.0x normal volume
- Closed at $3.60, -16.28% vs the prior close of $4.30. Day range $3.59–$4.32, opened at $4.30.
- Volume was 515.00K shares, 2.0x its 50-day average of 255.29K — unusually heavy trading.
- Price is -34.0% vs its 50-day average ($5.45) and -7.7% vs its 200-day average ($3.90).
- 52-week range $1.00–$7.19; today's close sits at 42% of that range, 49.9% below the 52-week high.
- That makes 7 straight losses.
Oct 12, 2026 — ANTX dips 2.3% to $4.30, a 3-month low, 6 down days in a row
- Closed at $4.30, -2.27% vs the prior close of $4.40. Day range $4.24–$4.41, opened at $4.41.
- Volume was 298.50K shares, 1.2x its 50-day average of 254.33K.
- Price is -21.7% vs its 50-day average ($5.49) and +10.6% vs its 200-day average ($3.89).
- 52-week range $1.00–$7.19; today's close sits at 53% of that range, 40.2% below the 52-week high.
- That makes 6 straight losses.
Oct 9, 2026 — ANTX slides 6.0% to $4.40, a 3-month low, 5 down days in a row
- Closed at $4.40, -5.98% vs the prior close of $4.68. Day range $4.26–$4.67, opened at $4.65.
- Volume was 442.10K shares, 1.7x its 50-day average of 252.66K.
- Price is -20.2% vs its 50-day average ($5.51) and +13.7% vs its 200-day average ($3.87).
- 52-week range $1.00–$7.19; today's close sits at 55% of that range, 38.8% below the 52-week high.
- That makes 5 straight losses.
Oct 8, 2026 — ANTX slides 3.5% to $4.68, a 1-month low, 4 down days in a row
- Closed at $4.68, -3.51% vs the prior close of $4.85. Day range $4.43–$4.86, opened at $4.77.
- Volume was 427.80K shares, 1.7x its 50-day average of 247.72K.
- Price is -15.4% vs its 50-day average ($5.53) and +21.4% vs its 200-day average ($3.85).
- 52-week range $1.00–$7.19; today's close sits at 59% of that range, 34.9% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — ANTX slides 4.3% to $4.85, 3 down days in a row
- Closed at $4.85, -4.34% vs the prior close of $5.07. Day range $4.70–$5.06, opened at $5.02.
- Volume was 365.10K shares, 1.5x its 50-day average of 242.30K.
- Price is -12.4% vs its 50-day average ($5.54) and +26.4% vs its 200-day average ($3.84).
- 52-week range $1.00–$7.19; today's close sits at 62% of that range, 32.5% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — ANTX slides 9.6% to $5.07
- Closed at $5.07, -9.63% vs the prior close of $5.61. Day range $5.01–$5.60, opened at $5.39.
- Volume was 318.20K shares, 1.3x its 50-day average of 237.20K.
- Price is -8.4% vs its 50-day average ($5.54) and +32.8% vs its 200-day average ($3.82).
- 52-week range $1.00–$7.19; today's close sits at 66% of that range, 29.5% below the 52-week high.
Oct 5, 2026 — ANTX dips 1.8% to $5.61
- Closed at $5.61, -1.75% vs the prior close of $5.71. Day range $5.50–$5.86, opened at $5.69.
- Volume was 299.90K shares, 1.3x its 50-day average of 233.77K.
- Price is +1.4% vs its 50-day average ($5.53) and +47.7% vs its 200-day average ($3.80).
- 52-week range $1.00–$7.19; today's close sits at 74% of that range, 22.0% below the 52-week high.
Oct 2, 2026 — ANTX rises 1.6% to $5.71 on 2.0x normal volume
- Closed at $5.71, +1.60% vs the prior close of $5.62. Day range $5.51–$5.99, opened at $5.64.
- Volume was 451.30K shares, 2.0x its 50-day average of 226.72K — unusually heavy trading.
- Price is +3.5% vs its 50-day average ($5.52) and +51.2% vs its 200-day average ($3.78).
- 52-week range $1.00–$7.19; today's close sits at 76% of that range, 20.6% below the 52-week high.
- That makes 5 straight gains.
ANTX latest news & SEC filings
Every SEC filing by or about ANTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Marks Gilbert Lynn received an award of 2,283 shares on Oct 12, 2026; now holds 84,156
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Martin Patricia A. received an award of 389 shares on Oct 12, 2026; now holds 19,252
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Aziz Kabeer received an award of 2,465 shares on Oct 12, 2026; now holds 61,571
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Trenor Cameron C. Iii received an award of 116,667 shares on Sep 15, 2026; now holds 116,667
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 14, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Sep 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Readnour Robin Shane sold 585 shares at $6.02 (≈$3.52K) on Sep 9, 2026
- Readnour Robin Shane sold 523 shares at $6.02 (≈$3.15K) on Sep 9, 2026
- Readnour Robin Shane sold 585 shares at $6.02 (≈$3.52K) on Sep 9, 2026
- Readnour Robin Shane sold 523 shares at $6.02 (≈$3.15K) on Sep 9, 2026
- Readnour Robin Shane sold 585 shares at $6.02 (≈$3.52K) on Sep 9, 2026
- Readnour Robin Shane sold 523 shares at $6.02 (≈$3.15K) on Sep 9, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Readnour Robin Shane sold 4,725 shares at $6.02 (≈$28.44K) on Sep 8, 2026
- Readnour Robin Shane sold 5,294 shares at $6.02 (≈$31.87K) on Sep 8, 2026
- Readnour Robin Shane sold 4,725 shares at $6.02 (≈$28.44K) on Sep 8, 2026
- Readnour Robin Shane sold 5,294 shares at $6.02 (≈$31.87K) on Sep 8, 2026
- Readnour Robin Shane sold 4,725 shares at $6.02 (≈$28.44K) on Sep 8, 2026
- Readnour Robin Shane sold 5,294 shares at $6.02 (≈$31.87K) on Sep 8, 2026
- …plus 10 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$8.19M (prior year -$6.46M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.18 (prior year -$0.21) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade ANTX
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 17, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.75% (largest 16.3%). That is a volatile stock.
- Liquidity: about 327.47K shares (≈$1.11M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $3.38 vs a range of $1.00–$7.19 (38% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Robin Shane Readnour sold 585 shares on Sep 9, 2026.
- Latest filings: 10-Q Aug 11, 2026; 8-K Aug 11, 2026; 8-K Jun 9, 2026.
- Share count: 37.74M shares outstanding (Aug 6, 2026), +38.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ANTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.60 | 3.62 | 3.30 | 3.38 | 281.73K |
| Oct 15, 2026 | 3.50 | 3.69 | 3.50 | 3.60 | 295.90K |
| Oct 14, 2026 | 3.55 | 3.73 | 3.33 | 3.54 | 431.00K |
| Oct 13, 2026 | 4.30 | 4.32 | 3.59 | 3.60 | 515.00K |
| Oct 12, 2026 | 4.41 | 4.41 | 4.24 | 4.30 | 298.50K |
| Oct 9, 2026 | 4.65 | 4.67 | 4.26 | 4.40 | 442.10K |
| Oct 8, 2026 | 4.77 | 4.86 | 4.43 | 4.68 | 427.80K |
| Oct 7, 2026 | 5.02 | 5.06 | 4.70 | 4.85 | 365.10K |
| Oct 6, 2026 | 5.39 | 5.60 | 5.01 | 5.07 | 318.20K |
| Oct 5, 2026 | 5.69 | 5.86 | 5.50 | 5.61 | 299.90K |
| Oct 2, 2026 | 5.64 | 5.99 | 5.51 | 5.71 | 451.30K |
| Oct 1, 2026 | 5.29 | 5.73 | 5.16 | 5.62 | 509.40K |
| Sep 30, 2026 | 5.07 | 5.35 | 5.00 | 5.32 | 199.10K |
| Sep 29, 2026 | 4.99 | 5.20 | 4.76 | 5.09 | 178.80K |
| Sep 28, 2026 | 4.89 | 5.17 | 4.67 | 5.01 | 318.50K |
| Sep 25, 2026 | 4.91 | 4.95 | 4.71 | 4.88 | 155.10K |
| Sep 24, 2026 | 4.77 | 5.06 | 4.72 | 4.89 | 258.90K |
| Sep 23, 2026 | 4.86 | 4.95 | 4.67 | 4.83 | 306.20K |
| Sep 22, 2026 | 5.00 | 5.05 | 4.70 | 4.83 | 191.70K |
| Sep 21, 2026 | 5.06 | 5.25 | 4.92 | 4.96 | 305.20K |
About AN2 Therapeutics
AN2 Therapeutics (ANTX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in MENLO PARK, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1880438.
ANTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Kabeer Aziz | Director | Jul 10, 2026 |
| Eric Easom | Chief Executive Officer | Mar 23, 2026 |
| Margaret M Fitzpatrick | Director | Sep 2, 2026 |
| Gilbert Lynn Marks | Director | Jul 10, 2026 |
| Patricia A. Martin | Director | Jul 10, 2026 |
| Robin Shane Readnour | Director | Sep 11, 2026 |
| Melvin K Spigelman | Director | Mar 23, 2026 |
| Stephanie Wong | Director | Mar 23, 2026 |
| Joseph S Zakrzewski | Director | Aug 14, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Sanjay Chanda | Chief Development Officer | Mar 23, 2026 |
| Lucy Day | Chief Financial Officer | Mar 23, 2026 |
| Eric Easom | Chief Executive Officer | Mar 23, 2026 |
| Joshua M Eizen | See Remarks | Jul 10, 2026 |
| Stephen David Prior | Chief Strategy Officer | Jan 7, 2026 |
| Cameron C. Iii Trenor | Chief Medical Officer | Sep 16, 2026 |
| Sarah Joanne Williams | Principal Accounting Officer | Sep 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 9, 2026 | Robin Shane Readnour | Sale | 585 | $6.02 |
| Sep 9, 2026 | Robin Shane Readnour | Sale | 523 | $6.02 |
| Sep 9, 2026 | Robin Shane Readnour | Sale | 585 | $6.02 |
| Sep 9, 2026 | Robin Shane Readnour | Sale | 523 | $6.02 |
| Sep 9, 2026 | Robin Shane Readnour | Sale | 585 | $6.02 |
| Sep 9, 2026 | Robin Shane Readnour | Sale | 523 | $6.02 |
| Sep 9, 2026 | Robin Shane Readnour | Sale | 585 | $6.02 |
| Sep 9, 2026 | Robin Shane Readnour | Sale | 523 | $6.02 |
| Sep 8, 2026 | Robin Shane Readnour | Sale | 4,725 | $6.02 |
| Sep 8, 2026 | Robin Shane Readnour | Sale | 5,294 | $6.02 |
| Sep 8, 2026 | Robin Shane Readnour | Sale | 4,725 | $6.02 |
| Sep 8, 2026 | Robin Shane Readnour | Sale | 5,294 | $6.02 |
| Sep 8, 2026 | Robin Shane Readnour | Sale | 4,725 | $6.02 |
| Sep 8, 2026 | Robin Shane Readnour | Sale | 5,294 | $6.02 |
| Sep 8, 2026 | Robin Shane Readnour | Sale | 4,725 | $6.02 |
ANTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-35.17M | -1.16 | $-29.83M |
| Dec 31, 2024 | — | $-51.32M | -1.72 | $-49.26M |
| Dec 31, 2023 | — | $-64.73M | -2.74 | $-53.29M |
| Dec 31, 2022 | — | $-40.96M | -2.79 | $-33.46M |
| Dec 31, 2021 | — | $-21.54M | -10.64 | $-20.48M |
Latest balance sheet: total assets $81.68M, total liabilities $5.75M, cash $44.32M (as of Jun 30, 2026).
ANTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $5.87 |
| May 11, 2026 | 8-K Item 2.02 (results) | $4.72 |
| Mar 17, 2026 | 8-K Item 2.02 (results) | $5.00 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $1.18 |
| Mar 25, 2025 | 8-K Item 2.02 (results) | $1.50 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $1.01 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 28, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
| Aug 10, 2023 | 8-K Item 2.02 (results) | — |
| May 11, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ANTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.